No. | First author | Year | Age/sex | Location of primary lesion | Histological type | ly/v | Complete resection | Adjuvant chemotherapy | Recurrence | Prognosis |
---|---|---|---|---|---|---|---|---|---|---|
1 | Kawashima [14] | 2007 | 78/F | A | Poorly differentiated adenocarcinoma | ly3/v3 | Done | 5-FU/LV | Liver(4 M) | Dead(5 M) |
2 | Kanzaki [15] | 2009 | 68/M | T | Moderately differentiated adenocarcinoma | ly2/v3 | Done | FOLFOX4, UFT/LV | (–) | Alive(24 M) |
3 | Yamagami [16] | 2009 | 66/F | A | Moderately differentiated adenocarcinoma | ly2/v3 | Done | FOLFIRI | (–) | Alive(22 M) |
4 | Kamata [17] | 2015 | 70/F | A | Well-differentiated adenocarcinoma | ly1/v1 | Done | FOLFOX4 | (–) | Alive(9 M) |
5 | Tajima [18] | 2016 | 60/F | A | Moderately differentiated adenocarcinoma | ly3/v3 | no | (–) | Liver, dissemination | Dead(21 M) |
6 | Akabane [19] | 2018 | 48/F | A | Moderately differentiated adenocarcinoma | ly0/v2 | Done | CapeOx | (–) | Alive(17 M) |
7 | Kim SE [20] | 2019 | 46/F | A | Poorly differentiated adenocarcinoma | N.D | Done | FOLFIRI + Bev | (–) | Alive(12 M) |
8 | Greally M [21] | 2019 | 54/F | T | Mucinous adenocarcinoma | N.D | Done | FOLFIRI | (–) | Alive(18 M) |
9 | Fujii [22] | 2020 | 82/M | A | Moderately differentiated adenocarcinoma | N.D | Done | (–) | Liver (6 M) | Dead(8 M) |
10 | Our case | 72/M | T | Moderately differentiated adenocarcinoma | ly1/v1 | Done | (–) | (–) | Alive(36 M) |